| 任公卿,姚静.抗CTLA-4和PD-1免疫疗法在肿瘤治疗中的应用[J].济宁医学院学报,2021,44(5):356-361 |
| 抗CTLA-4和PD-1免疫疗法在肿瘤治疗中的应用 |
| The application of anti-CTLA-4 and anti-PD-1 immunotherapy in tumor treatment |
| 投稿时间：2020-10-10 |
| DOI：10.3969/j.issn.1000-9760.2021.05.013 |
| 中文关键词: 肿瘤免疫疗法;细胞毒性T淋巴细胞相关抗原4;程序性细胞死亡蛋白1;联合治疗 |
| 英文关键词: Tumor immunotherapy;CTLA-4;PD-1;Combination therapy |
| 基金项目:大学生创新训练计划项目（S201910443010）；济宁医学院教师科研扶持基金（JYFC2018KJ038） |
|
| 摘要点击次数: 1503 |
| 全文下载次数: 1513 |
| 中文摘要: |
| 免疫疗法是肿瘤学中发展最快的治疗策略之一，尤其是以抑制性受体为靶点的治疗手段。阻断细胞毒性T淋巴细胞相关抗原4（cytotoxic T lymphocyte associated antigen-4，CTLA-4）和程序性细胞死亡蛋白1（programmed death-1，PD-1）可以增强抗肿瘤免疫疗法。易普利姆玛（ipilimumab，商标名称为Yervoy）是一种CTLA-4抑制剂，已被FDA批准用于治疗晚期黑色素瘤；纳武单抗（nivolumab，商标名称为OPDIVO）是一种PD-1抑制剂，主要用于有过往治疗的晚期非小细胞肺癌（non-small cell lung cancer，NSCLC）患者。联合使用以CTLA-4与PD-1为靶点的抑制剂相比于单一抑制剂，效果相对较好且肿瘤患者的存活率更高。本文系统总结了在肿瘤治疗中，CTLA-4和PD-1抑制剂的相关作用及联合应用的最新进展，为靶点抑制剂免疫疗法提供参考。 |
| 英文摘要: |
| Objective Immunotherapy is one of the fastest-growing therapeutic strategies in oncology, especially those that target inhibitory receptors.Clinical studies have confirmed that blocking cytotoxic T lymphocyte associated antigen-4(CTLA-4) and programmed death-1(PD-1) can enhance anti-tumor immunotherapy.For example, ipilimumab(brand name Yervoy) is a CTLA-4 inhibitor that has been approved by the FDA for the treatment of advanced melanoma;nivolumab(brand name OPDIVO) is a PD-1 inhibitor, mainly used for advanced non-small cell lung cancer(NSCLC) patients with previous treatments.Compared with a single inhibitor, the combined use of inhibitors targeting CTLA-4 and PD-1 has a relatively better effect and a higher survival rate for cancer patients.This article systematically summarizes the latest developments in the related effects and combined application of CTLA-4 and PD-1 inhibitors in tumor treatment and provides reference for target inhibitor immunotherapy. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
